The acquisition expands Veracyte's bladder cancer franchise with a differentiated urine-based platform, but the first product launch is not expected until late 2028, limiting near-term revenue impact. Monitor for integration updates and any changes to 2026 guidance in upcoming 10-Q filings.
Price Chart
Executive Summary
Veracyte acquires Convergent Genomics for $150M upfront plus up to $30M in milestone payments, adding the UroAmp urinary tumor DNA platform for bladder cancer monitoring. The deal strengthens Veracyte's bladder cancer portfolio across urine, tissue, and blood, with the first UroAmp test expected to commercialize in late 2028. The acquisition is funded from cash and Veracyte is not updating its 2026 adjusted EBITDA guidance.
Key Financial Metrics
Key Facts
- Veracyte acquires Convergent Genomics for $150M upfront cash plus up to $30M in milestone payments tied to UroAmp reimbursement.
- UroAmp is a urine-based tumor DNA platform validated in non-muscle invasive bladder cancer (NMIBC) for therapy-response monitoring and surveillance.
- First UroAmp test expected to commercialize in late 2028, subject to reimbursement timelines.
- Veracyte is not updating its previously provided 2026 adjusted EBITDA guidance to reflect the acquisition.
- UroAmp is supported by nine peer-reviewed publications and over 40 posters/abstracts.
- In the RUMBLE study, utDNA-positive patients had 25% 12-month recurrence-free survival vs. 91% for utDNA-negative patients.
Financial Impact
$150M upfront cash plus up to $30M milestone payments; Veracyte not updating 2026 EBITDA guidance.
Risk Factors
- Integration risk and potential delays in UroAmp commercialization timeline.
- Reimbursement uncertainty for the first UroAmp test could affect milestone payments and revenue ramp.
- Competing liquid biopsy and urine-based tests may emerge in the NMIBC monitoring space.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3361535 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 17d ago | Press Release | $40.14 $43.36 | ▲ +8.02% | ▲ +5.89% | $45.61 (+13.63%) |
Sep 4, 2026 27d ago | Insider Cluster | $42.45 $40.14 | ▼ −5.44% | ▼ −4.32% | $45.61 (+7.44%) |
Jun 18, 2026 15w ago | 144 | $53.19 $60.49 | ▲ +13.72% | ▲ +15.79% | $45.61 (−14.25%) |
Jun 11, 2026 16w ago | Institutional Cluster | $47.33 $53.63 | ▲ +13.31% | ▲ +12.64% | $45.61 (−3.63%) |
Jun 5, 2026 17w ago | Insider Cluster | $48.73 $47.33 | ▲ +2.87% | ▲ +3.44% | $45.61 (+6.40%) |
Jun 5, 2026 17w ago | Insider Cluster | $48.73 $47.33 | ▼ −2.87% | ▼ −3.44% | $45.61 (−6.40%) |
May 27, 2026 18w ago | Insider Cluster | $47.99 $49.94 | ▲ +4.06% | ▲ +3.75% | $45.61 (−4.96%) |
May 20, 2026 19w ago | 144 | $45.19 $47.99 | ▲ +6.20% | ▲ +4.60% | $45.61 (+0.93%) |
May 5, 2026 21w ago | 8-K | $41.19 $39.56 | ▼ −3.96% | ▼ −5.09% | $45.61 (+10.73%) |
Apr 22, 2026 23w ago | DEFA14A | $33.15 $31.78 | ▼ −4.13% | ▼ −5.61% | $45.61 (+37.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access